Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-Amyloid 42: A cross-validation study against amyloid positron emission tomography

JAMA Neurology

Volumn 71, Issue 10, 2014, Pages 1282-1289

  Palmqvist, Sebastian ^a,b   Zetterberg, Henrik ^c   Blennow, Kaj ^c   Vestberg, Susanna ^d,e   Andreasson, Ulf ^c   Brooks, David J ^f,g   Owenius, Rikard ^h   Hägerström, Douglas ^b   Wollmer, Per ^d   Minthon, Lennart ^a   Hansson, Oskar ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g AARHUS UNIVERSITY   (Denmark)

^h GE Healthcare Life Sciences   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; FLUTEMETAMOL F 18; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; FLUTEMETAMOL; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; AGED; APOE GENE; ARTICLE; BRAIN CORTEX; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISODIC MEMORY; FEMALE; GENOTYPE; GOLD STANDARD; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PATIENT CODING; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PREDICTION; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEFECT; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RELIABILITY; SENSITIVITY AND SPECIFICITY; SEX; SYMPTOM; VALIDATION STUDY; VALIDITY; ALZHEIMER DISEASE; BRAIN; CEREBROSPINAL FLUID; CINGULATE GYRUS; EARLY DIAGNOSIS; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BENZOTHIAZOLES; BRAIN; CEREBRAL CORTEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84907978955     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1358     Document Type: Article

References (49)

1. McGeer PL,McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathol. 2013;126(4): 479-497.
2. Blennow K, Hampel H,Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3): 131-144.
3. Jack CR Jr, Knopman DS, JagustWJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1): 119-128.
4. Buchhave P, Minthon L, Zetterberg H,Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1): 98-106.
5. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4): 403-413.
6. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA Study: A prospective cohort study. Lancet Neurol. 2009;8(7): 619-627.
7. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study. Lancet Neurol. 2013;12(10): 957-965.
8. Mattsson N, Andreasson U, Persson S, et al; Alzheimer's Association QC ProgramWork Group. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9(3): 251-261.
9. Clark CM, Pontecorvo MJ, Beach TG, et al; AV-45-A16 Study Group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study. Lancet Neurol. 2012;11 (8): 669-678.
10. Driscoll I, Troncoso JC, Rudow G, et al. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol. 2012; 124(6): 823-831.
11. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3): 306-319.
12. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol. 2010;68(3): 319-329.
13. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68(11): 1398-1403.
14. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3): 512-519.
15. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1(8-9): 371-380.
16. Forsberg A, Almkvist O, Engler H,Wall A, Långström B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010;7(1): 56-66.
17. Grimmer T, Riemenschneider M, Förstl H, et al. Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65(11): 927-934.
18. JagustWJ, Landau SM, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15): 1193-1199.
19. Koivunen J, Pirttilä T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-Amyloid inmild cognitive impairment. Dement Geriatr Cogn Disord. 2008;26(4): 378-383.
20. Landau SM, Lu M, Joshi AD, et al; Alzheimer's Disease Neuroimaging Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-Amyloid. Ann Neurol. 2013;74(6): 826-836.
21. Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009; 50(9): 1464-1470.
22. Weigand SD, Vemuri P,Wiste HJ, et al; Alzheimer's Disease Neuroimaging Initiative. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement. 2011;7(2): 133-141.
23. FolsteinMF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3): 189-198.
24. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2): 135-160.
25. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods: Application of linear regression procedures formethod comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem. 1983;21(11): 709-720.
26. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-Amyloid(1-42) in Alzheimer disease: Differences between early-And late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6): 673-680.
27. Blennow K,Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3): 231-245.
28. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285(1): 49-52.
29. KooleM, Lewis DM, Buckley C, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50(5): 818-822.
30. Lundqvist R, Lilja J, Thomas BA, et al. Implementation and validation of an adaptive template registrationmethod for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8): 1472-1478.
31. Strauss E, Sherman E, Spreen O. A Compendium of Neuropsychological Tests. 3rd ed. Oxford, England: Oxford University Press Inc; 2006.
32. Benaglia T, Chauveau D, Hunter DR, Young D. Mixtools: An R package for analyzing finite mixture models. J Stat Software. 2009;32(6): 1-29.
33. Altman DG. Practical Statistics for Medical Research. London, England: Chapman and Hall; 1991.
34. Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H. Analytical aspects of molecular Alzheimer's disease biomarkers. Biomark Med. 2012;6(4): 377-389.
35. BjerkeM, Portelius E,Minthon L, et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid [published online July 15, 2010]. Int J Alzheimers Dis. doi: 10.4061/2010/986310
36. Sancesario GM, Esposito Z, Nuccetelli M, et al. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible Abeta1-42 aggregation? Exp Neurol. 2010;223(2): 371-376.
37. Mattsson N, Andreasson U, Carrillo MC, et al. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. Biomark Med. 2012;6(4): 401-407.
38. Mattsson N, Zegers I, Andreasson U, et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: Definitions and approaches with focus on amyloid β42. Biomark Med. 2012;6(4): 409-417.
39. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010; 9(7): 560-574.
40. Kapaki E, Liappas I, Paraskevas GP, Theotoka I, Rabavilas A. The diagnostic value of tau protein, beta-Amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages. Int J Geriatr Psychiatry. 2005;20(8): 722-729.
41. Sjögren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values. Clin Chem. 2001;47(10): 1776-1781.
42. Vanderstichele H, De Vreese K, Blennow K, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006;44(12): 1472-1480.
43. Zetterberg H,Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett. 2003;352(1): 67-69.
44. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1): 122-131.
45. Villemagne VL, Burnham S, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol. 2013;12(4): 357-367.
46. Buchhave P, Blennow K, Zetterberg H, et al. Longitudinal study of CSF biomarkers in patientswith Alzheimer's disease. PLoS One. 2009;4(7): E6294.
47. Mattsson N, Portelius E, Rolstad S, et al. Longitudinal cerebrospinal fluid biomarkers over four years inmild cognitive impairment. J Alzheimers Dis. 2012;30(4): 767-778.
48. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131(pt 3): 665-680.
49. Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain. 2013;136(pt 7): 2217-2227.